DanDrit Biotech USA, Inc. (OTC: DDRT) was founded in 2001 and is focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer. DanDrit was founded based on the research of Professor Jesper Zeuthen at the Danish Cancer Society (Kraeftens Bekaempelse). Dendritic cells are critical components of the immune system. The ability of dendritic cells to induce a strong immune response is the basis of the vaccine therapies under development at DanDrit. The company’s expertise in producing dendritic cells from a patient’s blook is combined with conventional production methods to make new and advanced vaccines for cancer patients. For more information, visit the company’s website at www.dandrit.com